New approaches for the treatment of diabetic macular oedema

Recommendations by an expert panel

F. Bandello, J. Cunha-Vaz, N. V. Chong, G. E. Lang, P. Massin, P. Mitchell, M. Porta, C. Prünte, R. Schlingemann, U. Schmidt-Erfurth

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The current standard therapy for patients with diabetic macular oedema (DME)Ffocal/grid laser photocoagulation Fusually does not improve impaired vision, and many patients lose vision despite laser therapy. Recent approval of ranibizumab by the European Medicines Agency to treat visual impairment due to DME fulfils the previously unmet medical need for a treatment that can improve visual acuity (VA) in these patients. We reviewed 1- and 2-year clinical trial findings for ranibizumab used as treatment for DME to formulate evidence-based treatment recommendations in the context of this new therapy. DME with or without visual impairment should be considered for treatment when it fulfils the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria for clinically significant oedema. For DME with centre involvement and associated vision loss due to DME, monthly ranibizumab monotherapy with treatment interruption and re-initiation based on VA stability is recommended. Laser therapy based on ETDRS guidelines is recommended for other forms of clinically significant DME without centre involvement or when no vision loss has occurred, despite centre involvement. Because these recommendations are based on randomised controlled trials of 1-2 years duration, guidance may need updating as long-term ranibizumab data become available and as additional therapeutic agents are assessed in clinical trials.

Original languageEnglish
Pages (from-to)485-493
Number of pages9
JournalEye (London, England)
Volume26
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Macular Edema
Therapeutics
Vision Disorders
Laser Therapy
Diabetic Retinopathy
Visual Acuity
Clinical Trials
Light Coagulation
Edema
Lasers
Randomized Controlled Trials
Guidelines

Keywords

  • diabetic retinopathy
  • expert recommendations
  • vascular endothelial growth factor inhibitors

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Bandello, F., Cunha-Vaz, J., Chong, N. V., Lang, G. E., Massin, P., Mitchell, P., ... Schmidt-Erfurth, U. (2012). New approaches for the treatment of diabetic macular oedema: Recommendations by an expert panel. Eye (London, England), 26(4), 485-493. https://doi.org/10.1038/eye.2011.337

New approaches for the treatment of diabetic macular oedema : Recommendations by an expert panel. / Bandello, F.; Cunha-Vaz, J.; Chong, N. V.; Lang, G. E.; Massin, P.; Mitchell, P.; Porta, M.; Prünte, C.; Schlingemann, R.; Schmidt-Erfurth, U.

In: Eye (London, England), Vol. 26, No. 4, 04.2012, p. 485-493.

Research output: Contribution to journalArticle

Bandello, F, Cunha-Vaz, J, Chong, NV, Lang, GE, Massin, P, Mitchell, P, Porta, M, Prünte, C, Schlingemann, R & Schmidt-Erfurth, U 2012, 'New approaches for the treatment of diabetic macular oedema: Recommendations by an expert panel', Eye (London, England), vol. 26, no. 4, pp. 485-493. https://doi.org/10.1038/eye.2011.337
Bandello, F. ; Cunha-Vaz, J. ; Chong, N. V. ; Lang, G. E. ; Massin, P. ; Mitchell, P. ; Porta, M. ; Prünte, C. ; Schlingemann, R. ; Schmidt-Erfurth, U. / New approaches for the treatment of diabetic macular oedema : Recommendations by an expert panel. In: Eye (London, England). 2012 ; Vol. 26, No. 4. pp. 485-493.
@article{f232d149dfcc495a85337e5fdf2a2431,
title = "New approaches for the treatment of diabetic macular oedema: Recommendations by an expert panel",
abstract = "The current standard therapy for patients with diabetic macular oedema (DME)Ffocal/grid laser photocoagulation Fusually does not improve impaired vision, and many patients lose vision despite laser therapy. Recent approval of ranibizumab by the European Medicines Agency to treat visual impairment due to DME fulfils the previously unmet medical need for a treatment that can improve visual acuity (VA) in these patients. We reviewed 1- and 2-year clinical trial findings for ranibizumab used as treatment for DME to formulate evidence-based treatment recommendations in the context of this new therapy. DME with or without visual impairment should be considered for treatment when it fulfils the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria for clinically significant oedema. For DME with centre involvement and associated vision loss due to DME, monthly ranibizumab monotherapy with treatment interruption and re-initiation based on VA stability is recommended. Laser therapy based on ETDRS guidelines is recommended for other forms of clinically significant DME without centre involvement or when no vision loss has occurred, despite centre involvement. Because these recommendations are based on randomised controlled trials of 1-2 years duration, guidance may need updating as long-term ranibizumab data become available and as additional therapeutic agents are assessed in clinical trials.",
keywords = "diabetic retinopathy, expert recommendations, vascular endothelial growth factor inhibitors",
author = "F. Bandello and J. Cunha-Vaz and Chong, {N. V.} and Lang, {G. E.} and P. Massin and P. Mitchell and M. Porta and C. Pr{\"u}nte and R. Schlingemann and U. Schmidt-Erfurth",
year = "2012",
month = "4",
doi = "10.1038/eye.2011.337",
language = "English",
volume = "26",
pages = "485--493",
journal = "Eye",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - New approaches for the treatment of diabetic macular oedema

T2 - Recommendations by an expert panel

AU - Bandello, F.

AU - Cunha-Vaz, J.

AU - Chong, N. V.

AU - Lang, G. E.

AU - Massin, P.

AU - Mitchell, P.

AU - Porta, M.

AU - Prünte, C.

AU - Schlingemann, R.

AU - Schmidt-Erfurth, U.

PY - 2012/4

Y1 - 2012/4

N2 - The current standard therapy for patients with diabetic macular oedema (DME)Ffocal/grid laser photocoagulation Fusually does not improve impaired vision, and many patients lose vision despite laser therapy. Recent approval of ranibizumab by the European Medicines Agency to treat visual impairment due to DME fulfils the previously unmet medical need for a treatment that can improve visual acuity (VA) in these patients. We reviewed 1- and 2-year clinical trial findings for ranibizumab used as treatment for DME to formulate evidence-based treatment recommendations in the context of this new therapy. DME with or without visual impairment should be considered for treatment when it fulfils the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria for clinically significant oedema. For DME with centre involvement and associated vision loss due to DME, monthly ranibizumab monotherapy with treatment interruption and re-initiation based on VA stability is recommended. Laser therapy based on ETDRS guidelines is recommended for other forms of clinically significant DME without centre involvement or when no vision loss has occurred, despite centre involvement. Because these recommendations are based on randomised controlled trials of 1-2 years duration, guidance may need updating as long-term ranibizumab data become available and as additional therapeutic agents are assessed in clinical trials.

AB - The current standard therapy for patients with diabetic macular oedema (DME)Ffocal/grid laser photocoagulation Fusually does not improve impaired vision, and many patients lose vision despite laser therapy. Recent approval of ranibizumab by the European Medicines Agency to treat visual impairment due to DME fulfils the previously unmet medical need for a treatment that can improve visual acuity (VA) in these patients. We reviewed 1- and 2-year clinical trial findings for ranibizumab used as treatment for DME to formulate evidence-based treatment recommendations in the context of this new therapy. DME with or without visual impairment should be considered for treatment when it fulfils the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria for clinically significant oedema. For DME with centre involvement and associated vision loss due to DME, monthly ranibizumab monotherapy with treatment interruption and re-initiation based on VA stability is recommended. Laser therapy based on ETDRS guidelines is recommended for other forms of clinically significant DME without centre involvement or when no vision loss has occurred, despite centre involvement. Because these recommendations are based on randomised controlled trials of 1-2 years duration, guidance may need updating as long-term ranibizumab data become available and as additional therapeutic agents are assessed in clinical trials.

KW - diabetic retinopathy

KW - expert recommendations

KW - vascular endothelial growth factor inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84859782745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859782745&partnerID=8YFLogxK

U2 - 10.1038/eye.2011.337

DO - 10.1038/eye.2011.337

M3 - Article

VL - 26

SP - 485

EP - 493

JO - Eye

JF - Eye

SN - 0950-222X

IS - 4

ER -